Clinical trials: Recurrent GBM
Recurrent Glioblastoma
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the…
- Trial name
- MAGIC-G1 (NCT05324501)
- Testing
- MTX110, Programmable pump and catheter system
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Biodexa Pharmaceuticals
Supratentorial Neoplasms, Malignant, Malignant Glioma
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor.
- Conditions
- Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02457845
- Testing
- G207
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gregory K. Friedman, MD
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Glioma, Glioblastoma
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT01478178
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Kintara Therapeutics, Inc.
Recurrent Glioblastoma
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
- Trial name
- NCT00586508
- Testing
- enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Eli Lilly and Company
Glioblastoma, Nervous System Neoplasms
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
Patients with recurrent glioblastoma who are planned to receive a second course of radiation are to be included into this monocentric cohort trial.
- Conditions
- Glioblastoma, Nervous System Neoplasms, Central Nervous System Neoplasms, Astrocytoma
- Trial name
- NCT01579253
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Ludwig-Maximilians - University of Munich
High Grade Glioma
Nimotuzumab in Children With HGG
Determination of efficiency of nimotuzumab in children with high grade glioma.
- Trial name
- NCT00561873
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Oncoscience AG
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
The purpose of the study is to determine the safety and efficacy of intracranially implanted Carmustine in the treatment of patients with recurrent malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma
- Trial name
- NCT01637753
- Testing
- Carmustine(BCNU), Surgery
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
Glioblastoma Multiforme of Brain
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
This is a phase 1b study to evaluate the safety of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain (ie, CHM-1101, the study treatment) to determine the best dose of CHM-1101, and to assess the…
- Trial name
- NCT05627323
- Testing
- CHM-1101 CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Chimeric Therapeutics
Brain and Central Nervous System Tumors
Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have…
- Trial name
- NCT00004937
- Testing
- acridine carboxamide
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioblastoma Multiforme
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
- Trial name
- NCT04765098
- Testing
- Tamoxifen, Etoposide
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- AHS Cancer Control Alberta
Recurrent Glioblastoma
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.
- Trial name
- NCT04952571
- Testing
- Camrelizumab and Bevacizumab
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Beijing Sanbo Brain Hospital
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with…
- Trial name
- NCT00227032
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Glioblastoma, IDH-Wildtype
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma.
- Trial name
- Cerebraca-02/3 (NCT07349693)
- Testing
- Cerebraca wafer, Temozolomide (for relapsed malignant glioma)
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Everfront Biotech Co., Ltd.
Brain and Central Nervous System Tumors
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00006263
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- United States
- Sponsor
- NYU Langone Health
Glioblastoma, Recurrent Glioblastoma
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent).
- Trial name
- NCT04590664
- Testing
- Verteporfin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Glioblastoma Multiforme
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
- Trial name
- NCT01260506
- Testing
- VB-111, Bevacizumab
- Where
- 4 sites in United States, Israel
- Volunteers
- 75 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Brain and Central Nervous System Tumors
Procarbazine in Treating Patients With Recurrent Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of procarbazine in treating patients who have…
- Trial name
- NCT00004004
- Testing
- procarbazine hydrochloride
- Where
- 10 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium